Nyxoah shares fall after CFO departure announcement

Nyxoah SA's shares declined 2% in after-hours trading on Monday after the medical technology company announced that its Chief Financial Officer, John Landry, would resign effective October 2, 2026 to accept another professional opportunity. Loïc Moreau, Nyxoah's President International and former CFO, will take over as interim CFO upon Landry's departure.

The company has initiated a search for a permanent replacement. Moreau, who joined Nyxoah in 2022, has over 20 years of finance experience, including senior roles at GSK. He previously served as CFO before transitioning to the position of President International in 2024. Despite this leadership change, Nyxoah has reaffirmed its financial guidance for the full year 2026, with worldwide net revenue expected to be between €36 million and €40 million and a gross margin ranging from 60% to 62%.

The company anticipates total operating expenses to be between €99 million and €102 million, with non-GAAP cash operating expenses projected to be in the range of €88 million to €90 million. Nyxoah's primary product is the Genio system, a leadless and battery-free hypoglossal neurostimulation therapy for Obstructive Sleep Apnea.